Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Gandara

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicitiesD R Gandara, W A Nahhas, M D Adelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1992
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomitingT M Beck, P J Hesketh, S Madajewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancerD H Lau, J J Crowley, D R Gandara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805K S Albain, V W Rusch, J J Crowley, et al.
Cancer|September 1, 1991
Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancerR W Carlson, B I Sikic, D R Gandara, et al.
Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic studyS M Grunberg, J Crowley, K R Hande, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2005
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group studyH L West, J J Crowley, R B Vance, et al.
Cancer Chemotherapy and Pharmacology|October 27, 1998
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinicallyP N Lara, D R Gandara, G T Wurz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group studyA J Wozniak, J J Crowley, S P Balcerzak, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicitiesD R Gandara, W A Nahhas, M D Adelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1992
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomitingT M Beck, P J Hesketh, S Madajewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancerD H Lau, J J Crowley, D R Gandara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805K S Albain, V W Rusch, J J Crowley, et al.
Cancer|September 1, 1991
Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancerR W Carlson, B I Sikic, D R Gandara, et al.
Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic studyS M Grunberg, J Crowley, K R Hande, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2005
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group studyH L West, J J Crowley, R B Vance, et al.
Cancer Chemotherapy and Pharmacology|October 27, 1998
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinicallyP N Lara, D R Gandara, G T Wurz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group studyA J Wozniak, J J Crowley, S P Balcerzak, et al.
Pageof 9